(Q28281519)

English

Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis

scientific article

In more languages

Statements

scholarly article

0 references

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

Europe PubMed Central

Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis (English)

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

Kristian Thorlund

2

0 references

4

object named as

Steve Kanters

0 references

object named as

Sanni Yaya

5

0 references

Edward J. Mills

7

object named as

Edward J Mills

0 references

author name string

Eric Druyts

1

0 references

Ping Wu

3

0 references

Steve Kanters

4

0 references

Curtis L Cooper

6

0 references

language of work or name

0 references

publication date

April 2013

0 references

Clinical Infectious Diseases

0 references

56

0 references

7

0 references

961-7

0 references

Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Guidance for clinical trials for children and adolescents with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Current treatment options and response rates in children with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Treatment of hepatitis C in children: a systematic review

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Chronic hepatitis C virus infection in children and adolescents: Epidemiology, natural history, and assessment of the safety and efficacy of combination therapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Hepatitis C in children: a quaternary referral center perspective

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Early virological response in children with chronic hepatitis C treated with pegylated interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Impact of Hepatitis C Virus Infection on Children and Their Caregivers: Quality of Life, Cognitive, and Emotional Outcomes

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in Japanese pediatric and young adult patients: a survey of the Japan Society of Pediatric Hepatology

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Efficacy and safety of pegylated interferon in children and adolescents infected with chronic hepatitis C: a preliminary study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Management of chronic hepatitis C in childhood: the impact of therapy in the clinical practice during the first 2 decades

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Treatment and follow up of children with chronic hepatitis C in Albania

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS1031

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28281519&oldid=1953967579"